Prosecution Insights
Last updated: November 20, 2026

Barry A Chestnut, USPTO Patent Examiner

Listed by the USPTO as CHESTNUT, BARRY A

Tech Center 1600 • Art Units: 1646 1648 1671 1672

This examiner grants 74% of resolved cases

Analysis

CHESTNUT, BARRY A is assigned to tech center 1600 and art unit 1646. The profile records 766 resolved cases, with an allowance rate of 74.0% and a median of 993 days to allowance. The large docket shows allowance in most recorded cases, while the median timing indicates that applicants should plan for a substantial prosecution period.

The 6.2% interview lift is limited, placing greater practical weight on the written record and claim strategy. The principal companies are Zoetis LLC, The Board of Trustees of the Leland Stanford Junior University, and Merck Sharp & Dohme LLC. The leading firms are BANNER & WITCOFF, LTD., BOZICEVIC, FIELD & FRANCIS LLP, and Casimir Jones, S.C.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

74.0%
Allow Rate
+14.0% vs TC avg
794
Total Applications
+6.2%
Interview Lift
993
Avg Prosecution Days
Based on 766 resolved cases, 2023–2026

Rejection Statute Breakdown

4.7%
§101 Eligibility
20.5%
§102 Novelty
42.7%
§103 Obviousness
22.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18894405 OIL-BASED ADJUVANTS Non-Final OA Zoetis Services LLC
18721719 COMPOSITIONS AND METHODS FOR PREVENTION OF PISCINE MYOCARDITIS Non-Final OA Zoetis Services LLC
18364753 GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18769900 SCALABLE CHROMATOGRAPHY PROCESS FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS Non-Final OA Merck Sharp & Dohme LLC
18701156 MRNA VACCINE DESIGN VIA THE ALTERATION OF CODON USAGE Non-Final OA The Cleveland Clinic Foundation
18827183 SELF-REPLICATING RNA AND USES THEREOF Non-Final OA TRUSTEES OF BOSTON UNIVERSITY
18794860 FELINE LEUKEMIA VIRUS VACCINE Non-Final OA INTERVET INC.
18744397 Method of Generating Phage Clones with Expanded Activity Non-Final OA The Government of the United States, as Represented by The Secretary of The Army
18658604 SELF-AMPLIFYING RNA COMPOSITIONS AND METHODS OF USE THEREOF Non-Final OA Gritstone bio, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Barry A Chestnut's allowance rate?

74.0% of resolved applications examined by Barry A Chestnut were allowed (766 resolved cases), compared with 41.0% across Art Unit 1646 over the last five years.

Does an interview help with examiner Barry A Chestnut?

This examiner's interview lift is +6.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Barry A Chestnut take to allow a patent?

Applications allowed by Barry A Chestnut took 993 days on average from filing to allowance.

Which art unit does examiner Barry A Chestnut work in?

Barry A Chestnut examines applications in Art Unit 1646 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month